Skip to content

    Substance Abuse and Addiction Health Center

    Font Size

    Antidepressant May Ease Meth Addiction

    Depression Drug Showed Promise in First, Small Study
    WebMD Health News
    Reviewed by Louise Chang, MD

    Nov. 23, 2005 -- The depression drug bupropion (Wellbutrin, Zyban, Amfebutamone) may help treat addiction to the stimulant methamphetamine, also called "crank," "meth," and "speed."

    The finding comes from a small, brief study of meth users. It's too early to know if bupropion will become the first drug approved for treating meth addiction.

    The study by Thomas Newton, MD, and colleagues appears in the advance online edition of Neuropsychopharmacology. Newton is a psychiatry professor at the University of California, Los Angeles.

    Millions Affected

    Millions of Americans are directly or indirectly affected by meth addiction, the researchers write.

    They note that while current treatments (which focus more on behavior) work for some people, relapse remains a significant problem.

    In a news release, Newton says that "finding new, effective ways to treat methamphetamine addiction is a key component of bringing the ongoing epidemic of abuse under control."

    "Bupropion's novel effect on the brain is what makes this line of research so promising," he continues. "These findings may point the way toward medications with even greater potential to be helpful."

    Meth Study

    Newton's study included 26 active meth users, 20 of whom completed the study. They were 18-45 years old.

    None was seeking treatment for meth use. They also had no history of other illicit drug addictions, seizures, or other serious health problems.

    Participants were given bupropion or a fake pill (placebo) to take twice daily. Ten people from each group completed the study. They didn't know which pill they'd gotten.

    Before taking those pills, they were given small doses of meth in a lab. Then, they rated the drug's effects.

    Participants got another round of meth doses in the lab six days after taking bupropion or the placebo. Afterwards, they repeated their ratings.

    Lower High, Reduced Cravings

    Participants in the bupropion group reported a smaller "high" after the second round of meth doses. They also didn't seem to crave meth as much as those in the placebo group.

    To track meth cravings, participants rated their reactions to a video of actors simulating meth use. Watching others use drugs has been shown to trigger drug cravings in users.

    For comparison, participants also watched a video of nature scenes unrelated to drugs. As expected, the nature videos didn't prompt meth cravings in any participants.

    Today on WebMD

    child ignored by parents
    prescription pain pills
    Woman experiencing withdrawal symptoms
    Teen girl huddled outside house
    Man with glass of scotch
    overturned shot glass
    assortment of medication
    Depressed and hurting